🧫

Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation

active
experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-alpha-sy
🧫 Experiment Protocol Validationproposed
SUMMARY
# Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation ## Background and Rationale Alpha-synuclein aggregation represents a central pathological hallmark of Parkinson's disease and related synucleinopathies, yet the fundamental mechanisms governing the transition from functional monomer to pathogenic aggregates remain incompletely understood. While alpha-synuclein's physiological role involves binding to synaptic vesicles through its N-terminal amphipathic helices, the precise molecular e
METHODOLOGY NOTES
**Phase 1: Single-Molecule Biophysics Setup and Protein Preparation (Months 1-2)** Express and purify recombinant human alpha-synuclein and fluorescently-labeled variants (N-terminal ATTO488, C-terminal ATTO647N) using bacterial expression systems. Prepare synthetic lipid vesicles with varying compositions: pure DOPC, DOPC/DOPS (70:30), DOPC/DOPS/cholesterol (50:30:20), and brain-derived lipid extracts. Set up total internal reflection fluorescence (TIRF) microscopy system with dual-color imaging capability and temperature control. Establish single-molecule FRET (smFRET) assays to monitor conformational changes during membrane binding. Validate protein functionality using thioflavin-T aggregation assays and electron microscopy. **Phase 2: Membrane Binding Kinetics and Conformational Analysis (Months 3-5)** Perform single-molecule tracking experiments to measure alpha-synuclein binding kinetics to different membrane compositions. Use smFRET to monitor real-time conformational changes
Metadatasource: {'type': 'manual', 'source_name': 'wiki'
source{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.897275Z'}
summary# Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation ## Background and Rationale Alpha-synuclein aggregation represents a central pathological hallmark of Parkinson's disease and related synu
entities{'genes': ['YET'], 'diseases': ["Parkinson's Disease"]}
model_systemhuman
_schema_version1
experiment_typevalidation
primary_outcomeValidate Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
methodology_notes**Phase 1: Single-Molecule Biophysics Setup and Protein Preparation (Months 1-2)** Express and purify recombinant human alpha-synuclein and fluorescently-labeled variants (N-terminal ATTO488, C-termi
replication_statussingle_study
extraction_metadata{'backfill_at': '2026-04-16T01:00:16.897281', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}
📊 Evidence Profile Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
616
Outgoing
599
0 supporting 0 contradicting 0 neutral
View full evidence profile →
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.